WHITE BEAR LAKE, MINNESOTA – Envoy Medical®, Inc. (NASDAQ: “COCH”), a hearing health company dedicated to developing innovative solutions for hearing loss, announced the issuance of four new patents.
The U.S. Patent & Trademark Office issued Envoy Medical Corporation U.S. Patent No. 12,151,102 on November 25, 2024. Titled Combination Hearing Aid and Cochlear Implant System, the patent focuses on updating a transfer function within the implanted signal processor of a cochlear implant system. This allows compensation for external auditory aid devices, such as hearing aids, that alter input signals received by the cochlear implant system.
The European Patent Office will grant three additional patents to Envoy Medical Corporation, effective January 1, 2025:
- European Patent No. 4255554 – Combination Hearing Aid and Cochlear Implant System
This patent addresses cochlear implant systems capable of receiving status signals from external auditory aid devices. The system can adjust the transfer function of its signal processor to account for active external devices. - European Patent No. 4255555 – Cochlear Implant Stimulation Calibration
This innovation enables precise calibration of current flow in cochlear implant systems. A switching network controls communication between a source element and a testing circuit, ensuring accurate current adjustments. - European Patent No. 4319866 – Cochlear Implant System with Electrode Impedance Diagnostics
This patent focuses on electrode impedance diagnostics for cochlear implant systems. It determines impedance along the current path and adjusts stimulation parameters, such as compliance voltage, to optimize performance.
“We will continue to invest in the development and protection of intellectual property as we grow,” said Brent Lucas, CEO of Envoy Medical. “We intend for Envoy Medical to be synonymous with meaningful innovation in the hearing loss industry for decades to come.”
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss, allowing for 24/7 hearing capability using the ear’s natural anatomy. The Esteem FI-AMEI hearing implant is invisible, requires no externally worn components, and nothing is placed in the ear canal for it to function. Unlike hearing aids, it does not need to be put on or taken off, cannot be lost, and does not require cleaning. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
About the Fully Implanted Acclaim® Cochlear Implant
The fully implanted Acclaim Cochlear Implant (“Acclaim CI”) is anticipated to be a first-of-its-kind fully implanted cochlear implant. Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately managed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed suitable candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. It is believed that the Acclaim CI was the first hearing-focused device to receive Breakthrough Device Designation.
CAUTION: The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
Source: Envoy Medical
